Humana Inc. (NYSE:HUM) – Investment analysts at Oppenheimer Holdings lifted their Q4 2017 EPS estimates for shares of Humana in a note issued to investors on Wednesday. Oppenheimer Holdings analyst M. Wiederhorn now anticipates that the insurance provider will earn $2.13 per share for the quarter, up from their prior estimate of $1.96. Oppenheimer Holdings has a “Outperform” rating and a $255.00 price target on the stock. Oppenheimer Holdings also issued estimates for Humana’s Q1 2018 earnings at $2.74 EPS, Q3 2018 earnings at $3.58 EPS and Q4 2018 earnings at $2.47 EPS.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The firm had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. During the same period in the previous year, the business earned $2.30 earnings per share. COPYRIGHT VIOLATION WARNING: “Brokers Issue Forecasts for Humana Inc.’s Q4 2017 Earnings (HUM)” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/07/brokers-issue-forecasts-for-humana-inc-s-q4-2017-earnings-hum.html.

A number of other brokerages have also issued reports on HUM. Zacks Investment Research lowered Humana from a “buy” rating to a “hold” rating in a report on Monday, April 24th. Cowen and Company reiterated a “buy” rating and set a $230.00 price objective on shares of Humana in a research report on Friday, July 14th. Cantor Fitzgerald reiterated a “neutral” rating and set a $223.00 price objective (up previously from $200.00) on shares of Humana in a research report on Thursday. Jefferies Group LLC reiterated a “hold” rating and set a $257.00 price objective on shares of Humana in a research report on Friday. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $246.00 target price on shares of Humana in a report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $241.65.

In related news, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Heidi S. Margulis sold 1,500 shares of the stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the completion of the transaction, the vice president now directly owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The disclosure for this sale can be found here. Corporate insiders own 0.80% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Hermes Investment Management Ltd. increased its position in Humana by 0.9% in the first quarter. Hermes Investment Management Ltd. now owns 78,911 shares of the insurance provider’s stock valued at $16,267,000 after buying an additional 700 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in Humana during the first quarter valued at $342,000. Columbus Circle Investors boosted its stake in Humana by 97.4% in the first quarter. Columbus Circle Investors now owns 13,623 shares of the insurance provider’s stock valued at $2,808,000 after buying an additional 6,722 shares during the period. Granite Investment Advisors LLC boosted its stake in Humana by 12.1% in the first quarter. Granite Investment Advisors LLC now owns 2,410 shares of the insurance provider’s stock valued at $497,000 after buying an additional 260 shares during the period. Finally, Quantitative Systematic Strategies LLC purchased a new stake in Humana during the first quarter valued at $375,000. 99.66% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.